Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

PBS Biotech and denovoMATRIX Join Forces to Boost Manufacturing Processes for Cell & Gene Therapies

April 11, 2023 By Cade Hildreth, Founder & President Leave a Comment

Camarillo, CA (April 11, 2023) – PBS Biotech, an innovative, single-use bioreactor manufacturer and process development services provider, announces its collaboration with denovoMATRIX, a leading supplier of next-gen biomimetic coating technologies. By joining forces, PBS Biotech and denovoMATRIX seek to foster xeno-free expansion and scale-up of clinical-grade mesenchymal stromal cells (MSCs) and induced pluripotent stem cells (iPSCs) for use in allogeneic and autologous cell and gene therapies. The first outcome of this collaboration is a white paper presenting the advantages in MSC manufacturing that can be achieved using their cutting-edge technologies. [Read more…]

Growth Rates & Trends within the Cord Blood Industry – Interview with Kenneth Harris

February 21, 2023 By Cade Hildreth, Founder & President 2 Comments

The cord blood banking industry is often surrounded by misleading metrics, making insights from experts especially valuable. In an interview with Kenneth Harris, Chief Advisor for CuraSense Advisors, we delve into his extensive knowledge of the field. The discussion covers global growth rates, key trends shaping the industry, geographic differences in opportunities, and more, providing a comprehensive look at this evolving sector.

[Read more…]

FDA Grants RMAT Designation for Rexlemestrocel-L in Chronic Low Back Pain

February 11, 2023 By Cade Hildreth, Founder & President Leave a Comment

NEW YORK, Feb. 08, 2023 — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent for injection into the lumbar disc. [Read more…]

The Future Forecast for MSC-Based Therapeutics

January 27, 2023 By Cade Hildreth, Founder & President Leave a Comment

Presently, MSC-based clinical trials are being conducted for a range of disease conditions, with many completed trials showing safety and efficacy. Clinical utility of MSCs is primarily attributed to their four key biological properties, which include: [Read more…]

Athersys Provides MultiStem Clinical Update

January 23, 2023 By Cade Hildreth, Founder & President Leave a Comment

Enrollment completed in second cohort of MATRICS-1 trial in hemorrhagic trauma

Enrollment reaches halfway mark in MASTERS-2 trial in ischemic stroke

CLEVELAND–Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem^® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2). MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions. [Read more…]